Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Financing Activities (2016 - 2025)

Altimmune (ALT) has disclosed Cash from Financing Activities for 16 consecutive years, with $39.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 14692.86% to $39.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $135.8 million, a 86.76% increase, with the full-year FY2024 number at $10.0 million, down 88.34% from a year prior.
  • Cash from Financing Activities was $39.3 million for Q3 2025 at Altimmune, down from $52.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $72.8 million in Q4 2023 to a low of -$302000.0 in Q1 2023.
  • A 5-year average of $18.1 million and a median of $12.5 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 169295.35% in 2023; the steepest drop was 109.49% in 2023.
  • Altimmune's Cash from Financing Activities stood at $12.5 million in 2021, then plummeted by 100.34% to -$43000.0 in 2022, then soared by 169295.35% to $72.8 million in 2023, then crashed by 86.14% to $10.1 million in 2024, then soared by 290.17% to $39.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Cash from Financing Activities are $39.3 million (Q3 2025), $52.2 million (Q2 2025), and $34.1 million (Q1 2025).